We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00309504
First Posted: April 3, 2006
Last Update Posted: February 26, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta
  Purpose
The purpose of this study is to find ways to improve the appearance of tumours or markers that indicate the presence of tumours in Magnetic Resonance Imaging (MRI). Although based on the same technology, there are many ways to obtain images using MRI. The type of image that will be produced by the scanner depends on the instructions sent to the machine. These instructions tell different components of the machine when to turn on and off and all together are called a pulse sequence. These pulse sequences can get quite lengthy and intricate and small changes in them can produce considerable changes in the resulting image. the aim of this protocol is to alter existing pulse sequences to improve image appearance. This protocol will involve only healthy volunteers.

Condition
Healthy

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Pulse Sequence Development on 3T Magnetic Resonance Imaging/Spectroscopy

Resource links provided by NLM:


Further study details as provided by AHS Cancer Control Alberta:

Enrollment: 40
Study Start Date: March 2006
Study Completion Date: February 2012
Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Local Healthy volunteers
Criteria

Inclusion Criteria:

  • healthy adult

Exclusion Criteria:

  • subject under 18 years of age
  • subject pregnant, or may be pregnant
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00309504


Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Investigators
Principal Investigator: Gino B. Fallone, PhD, FCCPH, DABR AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00309504     History of Changes
Other Study ID Numbers: 22307
First Submitted: March 31, 2006
First Posted: April 3, 2006
Last Update Posted: February 26, 2016
Last Verified: March 2012

Keywords provided by AHS Cancer Control Alberta:
magnetic resonance imaging
magnetic resonance spectroscopy